Drug intelligence / Profile preview

RSS0393

Development stage: Phase 3
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

RSS0393 is a topical chemical drug under development for the treatment of psoriasis. It is classified as an antipsoriatic and skin disorder therapy. The drug is being developed by Jiangsu Hengrui Medicine and was initially developed by Reistone Biopharma. Its mechanism of action has not been defined or disclosed publicly. As of early 2025, its highest development phase is Phase 1 clinical trials for psoriasis, with ongoing studies evaluating its safety and pharmacokinetic profile in both healthy volunteers and patients with psoriasis.

Beyond the preview

Go deeper on RSS0393.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSS0393.

Explore the full profile